Related Experiment Video

Updated: Jun 22, 2025

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window
09:44

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window

Published on: November 20, 2012

13.1K

New targets for cancer promotion and therapy in gliomas: Scinderin

Xi Wang1, Lian-Xiang Luo2

  • 1The First Clinical College, Guangdong Medical University, Zhanjiang 524023, Guangdong Province, China.

World Journal of Clinical Oncology
|July 1, 2024
PubMed

Insights

Scinderin (SCIN) promotes glioma growth by altering the actin cytoskeleton and inhibiting cell migration. Targeting SCIN offers a potential new strategy for treating this aggressive brain tumor.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Glioma is a primary intracranial tumor with invasive growth and poor prognosis.
  • Actin cytoskeletal dynamics are crucial for tumor cell migration.
  • Scinderin (SCIN), an actin-binding protein, regulates the cytoskeleton but its role in glioma is unknown.

Discussion:

  • SCIN mechanically impacts cytoskeleton remodeling in glioma cells.
  • SCIN inhibits lamellipodia formation through the RhoA/FAK signaling pathway.
  • This suggests SCIN plays a pro-tumorigenic role in glioma progression.

Key Insights:

  • Scinderin (SCIN) is identified as a promoter of glioma.
  • SCIN influences glioma cell migration by affecting actin dynamics.
  • The RhoA/FAK pathway is implicated in SCIN-mediated effects.

Outlook:

  • SCIN represents a potential therapeutic target for glioma treatment.
  • Further research can explore SCIN-specific inhibitors for glioma therapy.
  • Understanding SCIN's mechanism could lead to novel anti-glioma strategies.
Keywords:
1p/19q co-deletionActin cytoskeletonGliomaRhoA/FAK signalingScinderin

More Related Videos

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.3K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K